



THE UNITED STATES PATENT AND TRADEMARK OFFICE  
Group Art Unit Unknown

In re

Patent Application of

Phillip Wilson Howard

Application No. 10/598,691

Confirmation No.: 9035

Filed: September 8, 2006

Examiner: Unknown

"PYRROLOBENZODIAZEPINES"

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97(b)

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

The Examiner's attention is directed to the references which are listed on the attached Form PTO/SB/08B; copies of non-U.S. patent references are attached.

Citation of these references is respectfully requested.


No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate.

Respectfully submitted,

  
Charlene L. Yager  
Reg. No. 48,887

File No. 065435-9082 US00  
Michael Best & Friedrich LLP  
One South Pinckney Street  
P. O. Box 1806  
Madison, WI 53701-1806  
608.257.3501

IFW



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	1	of	9	Attorney Docket Number	065435-9082 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		ABB, J., "In vitro activity of linezolid, quinupristin-dalfopristin, vancymycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method," <i>Diag. Microb. Inf. Disease</i> (2002) 43:319-321
		ADAMS et al., "Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines," <i>Pharm. Pharmacol. Commun.</i> (1999) 5:555-560
		ARIMA et al., "Studies on Tomaymycin, a New Antibiotic. I. Isolation and Properties of Tomaymycin," <i>J. Antibiotics</i> (1972) 25:437-444
		BABA, T. et al., "Genome and virulence determinants of high virulence community-acquired MRSA," <i>Lancet</i> (2002) 359:1819-1827
		BERGE et al., "Pharmaceutical Salts," <i>J. Pharm. Sci.</i> (1977) 66:1-19
		BERRY, J. M. et al., "Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," <i>Tetrahedron Letters</i> (2000) 41:6171-6174
		BOSE et al., "New Approaches to Pyrrolo[2,1-c][1,4]benzodiazepines: Synthesis, DNA-binding and cytotoxicity of DC-81," <i>Tetrahedron</i> , 48, 751-758 (1992)
		BOSE, D.S. et al., "Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System," <i>J. Am. Chem. Soc.</i> , 114, 4939-4941 (1992)
		BOSE, D.S. et al., "Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8 linked pyrrolobenzodiazepine dimers," <i>J. Chem. Soc. Chem. Commun.</i> (1992) 20:1518-1520

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	2	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		CHEN, Z. et al., "A novel approach to the synthesis of cytotoxic C2-C3 unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) with conjugated acrylyl C2-substituents," <i>Biorg. Med. Chem. Lett.</i> (2004) 14:1547-1549
		COOPER, N. et al., "Synthesis of novel PBDs as anti-tumour agents," <i>Chem. Commun.</i> (2002) 16:1764-1765
		COURTNEY, S. M. et al., "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Tetrahedron Letters</i> , vol. 34, No. 33, 5327-28 (1993)
		ENRIGHT, M.C., "The evolution of a resistant pathogen - the case of MRSA," <i>Curr. Opin. Pharmac.</i> (2003) 3:474-479
		FARMER, J.D. et al., "DNA binding properties of a new class of linked anthramycin analogs," <i>Chemical Abstracts</i> , Abstract No. 239940r, vol. 114, No. 25, 25 899-903 (1991)
		FOLOPPE, M.P. et al., "DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazepine N10-C11 amidines," <i>Eur. J. Med. Chem.</i> , 31, 407-410 (1996)
		FUJISAWA PHARMACEUTICAL CO., LTD., Abstract No. 139983k, "Benzodiazepine derivatives", <i>Chemical Abstracts</i> , vol. 99, No. 17, 603 (1983)
		FUJISAWA PHARMACEUTICAL CO., LTD., Abstract No. 72145x, "Benzodiazepine derivatives", <i>Chemical Abstracts</i> , vol. 98, No. 9, 638 (1983)
		FUJISAWA PHARMACEUTICAL CO. LTD., "Benzodiazepine derivatives," <i>SciFinder Scholar</i> , 2-3 (2002)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	3	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		FUKUYAMA, T. et al., "Total Synthesis of (+)-Porothramycin B," <i>Tetrahedron Letters</i> , vol. 34, 16, 2577-2580 (1993)
		GREENE, T.W. and WUTS, P.G.M., <i>Protective Groups in Organic Synthesis</i> , John Wiley & Sons, 2 <sup>nd</sup> ed., Ch 7, 315-345 (1991)
		GREGSON, S. et al., "Synthesis of a novel C2/C2'-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity," <i>Chemical Communications</i> , 797-798 (1999)
		GREGSON, S.J. et al., "Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo-[2,1-c][1,4]-benzodiazepines," <i>Bioorg. Med. Chem. Lett.</i> (2000) 10(16):1849-1851
		GREGSON, S.J. et al., "Design, Synthesis and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity", <i>J. Med. Chem.</i> , 44: 737-748 (2001)
		GREGSON, S.J. et al., "Effect of C2-exo Unsaturation on the Cytotoxicity and DNA-Binding Reactivity of Pyrrolo[2,1-c][1,4]benzodiazepines", <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10: 1845-1847 (2000)
		GREGSON, S.J. et al., "Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers," <i>J. Med. Chem.</i> (2004) 1161-1174
		GREGSON, S.J. et al., "Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer," <i>Biorg. Med. Chem. Lett.</i> (2001) 11:2859-2862
		GREGSON, S.J. et al., "Synthesis of the first examples of A-C8/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers," <i>Biorg. Med. Chem. Lett.</i> (2003) 13:2277-2280

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	4	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		GUIOTTO, A. et al., "Synthesis of novel C7-aryl substituted pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) via Pro-N10-troc protection and suzuki coupling," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 8, No. 21, 3017-3018 (1998)
		HARA et al., "DC 102, a new glycosidic pyrrolo(1,4)benzodiazepine antibiotic produced by <i>streptomyces</i> sp.", <i>J. Antibiotics</i> , 41, 702-704 (1988)
		HARTLEY, J.A. et al., "An agarose gel method for the determination of DNA interstrand crosslinking applicable to the measurement of the rate of total and 'second arm' crosslink reactions," <i>Anal. Biochem.</i> (1991) 193:131-134
		HIRAMATSU, K. et al., "The emergence of staphylococcus aureus with reduced susceptibility to vancomycin in Japan," <i>Am. J. Med.</i> (1998) 104(5A):7S-10S
		HOCHLOWSKI, J. et al., "Abbeymycin, a new anthramycin-type antibiotic produced by a streptomycete," <i>J. Antibiotics</i> , 40, 145-148 (1987)
		HURLEY, L. and NEEDHAM-VANDEVANTER, D., "Covalent Binding of Antitumor Antibiotics in the Minor Groove of DNA. Mechanism of Action of CC-1065 and the Pyrrolo(1,4)benzodiazepines," <i>Acc. Chem. Res.</i> , 19, 230-237 (1986)
		ITOH et al., "Sibanomicin, a new pyrrolo(1,4)benzodiazepine antitumor antibiotic produced by a <i>micromonospora</i> sp." <i>J. Antibiotics</i> , 41, 1281-1284 (1988)
		KAMAL, A., et al., "An Efficient Synthesis of Pyrrolo[2,1-c][1,4] Benzodiazepine Antibiotics via Reductive Cyclization," <i>Bioorg. Med. Chem. Ltrs</i> , 7, No. 14, 1825-1828 (1997)
		KAMAL, A., et al., "Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP", <i>Tetrahedron</i> , v. 53, No. 9, 3223-3230 (1997)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	5	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		KAMAL et al., "Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers" Biorg. Med. Chem. Lett. (2003) 13(22):3955-3958
		KAMAL, et al., "Synthesis of pyrrolo[2,1-c][1,4]benzodiazepines via reductive cyclization of w-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers," Biorg. Med. Chem. Lett. (2000) 10:2311-2313
		KANEKO, T. et al., "Bicyclic and tricyclic analogues of anthramycin," J. Med. Chem. (1985) 28:388-392
		KANG, G.-D. et al., "Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine," Chem. Commun. (2003) 1688-1689
		KOHN, K., "Anthramycin," <i>Antibiotics III</i> , Springer-Verlag, NY, 3-11 (1975)
		KONISHI, M. et al., "Chicamycin, a new antitumor antibiotic II. Structure determination of chicamycins A and B," <i>J. Antibiotics</i> , 37, 200-206 (1984)
		KUNIMOTO et al., "Mazethramycin, a new member of anthramycin group antibiotics," <i>J. Antibiotics</i> , 33, 665-667 (1980)
		LANGLEY, D.R. and THURSTON, D.E., "A versatile and efficient synthesis of carbinolamine-containing pyrrolo[1,4]benzodiazepines via the cyclization of N-92-aminobenzoylpyrrolidine-2-carboxaldehyde diethyl thioacetals: total synthesis of prothracarcin," <i>J. Org. Chem.</i> , 52, 91-97 (1987)
		LANGLOIS, N. et al., "Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin," <i>J. Med. Chem.</i> (2001) 44:3754-3757

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
Examiner Name	Unknown				
Sheet	6	of	9	Attorney Docket Number	065435-9082 US00

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		LEBER, J.D. et al., "A revised structure for sibiromycin," <i>J. Am. Chem. Soc.</i> , 110, 2992-2993 (1988)
		LEIMGRUBER, W. et al., "Isolation and characterization of anthramycin, a new antitumor antibiotic," <i>J. Am. Chem. Soc.</i> , 87, 5791-5793 (1965)
		LEIMGRUBER, W. et al., "The structure of anthramycin," <i>J. Am. Chem. Soc.</i> , 87, 5793-5795 (1965)
		LEIMGRUBER, W. et al., "Total synthesis of anthramycin," <i>J. Am. Chem. Soc.</i> , 90, 5641-5643 (1968)
		LOWN et al., "Molecular Mechanism of Binding of Pyrrolo(1,4)benzodiazepine antitumour agents to deoxyribonucleic acid – anthramycin and tomaymycin," <i>Biochem. Pharmacol.</i> (1979), 28 (13), 2017-2026
		MORI, M. et al., "Total syntheses of prothracarcin and tomaymycin by use of palladium catalyzed carbonylation," <i>Tetrahedron</i> (1986) 42(14):3793-3806
		MOUNTZOURIS, J.A. et al., "Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-Tomamycin adduct," <i>J. Med. Chem.</i> (1994) 37:3132-3140
		MUNOZ BELLIDO, J.L. et al., "In vitro activity of linezolid, synercid and telithromycin against genetically defined high level fluoroquinolone-resistant methicillin-resistant staphylococcus aureus," <i>Int. J. Antimicrob. Agents</i> (2002) 20:61-64
		NAGASAKA, T. and KOSEKI, Y., "Stereoselective Synthesis of Tilivalline," <i>Journal of Organic Chemistry</i> , vol. 63, No. 20, 6797-6801 (1998)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	7	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		NAGASAKA, T. et al., "Stereoselective Synthesis of Tilivalline," <i>Tetrahedron Letters</i> , 30:14, 1871-1872 (1989)
		O'NEIL, I.A., et al., "The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines," <i>Synlett</i> , 75-78 (1997)
		O'NEIL, Chemical Abstract No. 171573p, "The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines", <i>Chemical Abstracts</i> , vol. 126, No. 13, 618 (1997)
		O'NEIL, I.A. et al., "DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions", <i>Tetrahedron Letters</i> , vol. 39, No. 42, 7787-7790 (1998)
		QUIRK, M., "First VRSA isolate identified in USA," <i>The Lancet</i> (2002) 2:510
		SAGNOU, M.J. et al., "Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 10, 2083-2086 (2000)
		SHIMIZU, K et al., "Prothracarcin, a Novel Antitumor Antibiotic," <i>J. Antibiotics</i> , 35, 972-978 (1982)
		SPELLIE, M. et al., "Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents," <i>Br. J. Cancer</i> (1994) 70:48-53
		SPELLIE, M. et al., "Sequence selective recognition of duplex DNA through covalent interstrand cross-linking," <i>Biochem.</i> (2003) 42:8232-8239

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	8	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		SUGGS, J.W. et al., "Synthesis and structure of anthramycin analogs via hydride reduction of dilactams," <i>Tetrahedron Letters</i> , 26, No. 40, 4871-4874 (1985)
		TAKEUCHI, T. et al., "Neothramycins A and B, New Antitumor Antibiotics," <i>J. Antibiotics</i> , 29, 93-96 (1976)
		TERCEL, M. et al., "Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores," <i>J. Med. Chem.</i> (2003) 46:2132-2151
		THURSTON, D.E. and THOMPSON, A.S., "The molecular recognition of DNA," <i>Chem. Brit.</i> , 26, 767-772 (1990)
		THURSTON, D.E. and BOSE, D.S., "Synthesis of DNA-Interactive Pyrrolo[2,1-c][1,4]benzodiazepines," <i>Chem. Rev.</i> , 94:433-465 (1994)
		THURSTON, D. E., "Advances in the study of Pyrrolo[2,1-c][1,4] benzodiazepine (PBD) Antitumour Antibiotics", <i>Molecular Aspects of Anticancer Drug-DNA Interaction</i> , Neidle, S. and Waring, M.J., Eds.; Macmillan Press Ltd, 1:54-88 (1993)
		THURSTON, D.E. et al., "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Journal of Medicinal Chemistry</i> , 42:1951-1964 (1999)
		THURSTON, D.E. et al., "Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent," <i>J. Org. Chem.</i> , 61:8141-8147 (1996)
		THURSTON, D.E. et al., "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines (PBDs)," <i>Chemical Communications</i> , 563-565 (1996)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/598691
				Filing Date	September 8, 2006
				First Named Inventor	Phillip Wilson Howard
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	9	of	9	Attorney Docket Number	065435-9082 US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc. ), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		THURSTON, D.E., "Nucleic acid targeting: therapeutic strategies for the 21st century," Brit. J. Cancer (1999) 80(1):65-85
		TIBERGHEN, A.C. et al., "Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)," Biorg. Med. Chem. Lett. (2004) 14:5041-5044
		TSUNAKAWA, M. et al., "Porothramycin, a new antibiotic of the anthramycin group: Production, isolation, structure and biological activity," <i>J. Antibiotics</i> , 41:1366-1373 (1988)
		UMEZAWA, H. et al., Chemical Abstract No. 4427a, "Mazethramycins" <i>Chemical Abstracts</i> , vol. 90, No. 1, 428 (1979)
		UMEZAWA, H. et al., "Mazethramycins," <i>SciFinder Scholar</i> , 2-3 (2002)
		WILSON, S.C. et al., "Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure," <i>Tetrahedron Letters</i> , 36, No. 35, 6333-6336 (1995)
		WILSON, S.C. et al., "Design, Synthesis, and Evaluation of a Novel Sequence-Selective Epoxide-Containing DNA Cross-Linking Agent Based on the Pyrrolo[2,1-c][1,4]benzodiazepine System", <i>J. Med. Chem.</i> 42:4028-4041 (1999)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.